{
    "clinical_study": {
        "@rank": "159893", 
        "arm_group": [
            {
                "arm_group_label": "Control", 
                "arm_group_type": "No Intervention", 
                "description": "No tranexamic acid given"
            }, 
            {
                "arm_group_label": "Tranexamic Acid", 
                "arm_group_type": "Experimental", 
                "description": "15 mg/kg preoperative IV dose followed by another 15 mg/kg IV dose three hours after the initial dose"
            }
        ], 
        "brief_summary": {
            "textblock": "Tranexamic acid is an antifibrinolytic drug that has been used to decrease post-operative\n      blood loss.  This study is a prospective, randomized controlled trial investigating the use\n      of tranexamic acid in fracture surgery around the hip and knee, in which significant blood\n      loss (>300mL) is expected.\n\n      The hypothesis of this study is that tranexamic acid will be associated with a decrease in\n      post-operative blood loss, as well as a decreased need for allogenic blood transfusion, in\n      patients who have fracture surgery around the hip and knee."
        }, 
        "brief_title": "Tranexamic Acid in Orthopaedic Trauma Surgery", 
        "condition": [
            "Blood Loss", 
            "Trauma", 
            "Fracture", 
            "Surgery"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Fractures, Bone", 
                "Hemorrhage", 
                "Wounds and Injuries"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with isolated fractures of the pelvic ring, acetabulum, femur or tibia that\n             will require open reduction and internal fixation\n\n          -  Expected blood loss is greater than 300 mL\n\n          -  Age \u2265 18\n\n          -  Skeletal maturity\n\n        Exclusion Criteria:\n\n          -  Pregnant or breastfeeding\n\n          -  Patients taking oral contraceptives\n\n          -  Contraindication to venous thromboembolic event (VTE) prophylaxis (intracranial,\n             intrathoracic, intra-abdominal bleeding or spine fractures)\n\n          -  Patients requiring operative intervention for other injuries (orthopaedic or\n             non-orthopaedic)\n\n          -  Known hypercoagulable state including history of prescribed anti-coagulation\n             (warfarin, plavix, low molecular weight heparin)\n\n          -  Renal Insufficiency (creatinine greater than 1.5mg/dL)\n\n          -  Open fractures"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02080494", 
            "org_study_id": "11-036"
        }, 
        "intervention": {
            "arm_group_label": "Tranexamic Acid", 
            "intervention_name": "Tranexamic Acid", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Tranexamic Acid"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "tranexamic acid", 
            "orthopaedic trauma", 
            "pelvic fracture", 
            "hip fracture", 
            "femur fracture", 
            "blood loss"
        ], 
        "lastchanged_date": "March 5, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Chattanooga", 
                    "country": "United States", 
                    "state": "Tennessee", 
                    "zip": "37403"
                }, 
                "name": "Erlanger Health System"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Tranexamic Acid in Orthopaedic Trauma Surgery", 
        "overall_official": {
            "affiliation": "UTCOM Chattanooga / Erlanger Health System", 
            "last_name": "Dirk W Kiner, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "hemoglobin value", 
            "safety_issue": "No", 
            "time_frame": "through postoperative day four"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02080494"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "hematocrit value", 
                "safety_issue": "No", 
                "time_frame": "through postoperative day four"
            }, 
            {
                "measure": "number of units of allogenic blood transfused", 
                "safety_issue": "No", 
                "time_frame": "through postoperative day four"
            }
        ], 
        "source": "University of Tennessee", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Tennessee", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}